Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GZ-793A

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Varenicline and GZ-793A differentially decrease methamphetamine self-administration under a multiple schedule of reinforcement in rats
Methamphetamine is a potent psychostimulant with high abuse rates. Currently, there is no Food and Drug Administration-approved… Expand
Is this relevant?
2017
2017
GZ‐793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter‐2
ABSTRACT Lobeline and lobelane inhibit the behavioral and neurochemical effects of methamphetamine via an interaction with the… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2014
Review
2014
The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.
Methamphetamine abuse escalates, but no approved therapeutics are available to treat addicted individuals. Methamphetamine… Expand
Is this relevant?
2013
2013
Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats
Despite the high prevalence of use of methamphetamine (METH), there is no FDA-approved pharmacological treatment available… Expand
Is this relevant?
2013
2013
Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo.
Vesicular monoamine transporter-2 (VMAT2) inhibitors reduce methamphetamine (METH) reward in rats. The current study determined… Expand
Is this relevant?
2013
2013
GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine.
(R)-3-[2,6-cis-Di(4-methoxyphenethyl)piperidin-1-yl]propane-1,2-diol (GZ-793A) inhibits methamphetamine-evoked dopamine release… Expand
Is this relevant?
2013
2013
Pyrrolidine analogs of GZ-793A: synthesis and evaluation as inhibitors of the vesicular monoamine transporter-2 (VMAT2).
Central heterocyclic ring size reduction from piperidinyl to pyrrolidinyl in the vesicular monoamine transporter-2 (VMAT2… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats
RationaleThe vesicular monoamine transporter 2 (VMAT2) has been identified as a potential target for the treatment of… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2011
2011
The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats
RationalePrevious research suggests that the vesicular monoamine transporter-2 (VMAT2) is a novel target for the treatment of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
2011
2011
Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.
Lobelane, a chemically defunctionalized saturated analog of lobeline, has increased selectivity for the vesicular monoamine… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE